Respiratory syncytial virus associated hospitalizations in preterm infants of 29 to 32 weeks gestational age using a risk score tool for palivizumab prophylaxis

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 36, Issue 6, 2017, Pages 1057-1062

  Resch, B ^a   Bramreiter, V S ^a   Kurath Koller, S ^a   Freidl, T ^a   Urlesberger, B ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB; ANTIVIRUS AGENT;

ARTICLE; ARTIFICIAL VENTILATION; AUSTRIA; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; GESTATIONAL AGE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INFANT; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; OXYGEN SUPPLY; PREMATURITY; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; TERTIARY HEALTH CARE; CHEMOPROPHYLAXIS; FEMALE; MALE; NEWBORN; PATHOLOGY; PROCEDURES; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RISK ASSESSMENT; TERTIARY CARE CENTER; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

ANTIVIRAL AGENTS; AUSTRIA; CHEMOPREVENTION; FEMALE; HOSPITALIZATION; HOSPITALS, UNIVERSITY; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; MALE; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TERTIARY CARE CENTERS; TREATMENT OUTCOME;

EID: 85009233049     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-016-2891-6     Document Type: Article

References (35)

1. Resch B, Resch E, Müller W (2013) Should respiratory care in preterm infants include prophylaxis against respiratory syncytial virus infection? The case in favor. Paediatr Respir Rev 14:130–136
2. Resch B, Gusenleitner W, Müller WD, Haas J (2006) Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29–32 weeks. Eur J Clin Microbiol Infect Dis 25:120–122
3. Zaknun D, Resch B, Jürgenssen O, Sterniste W, Kaulfersch W, Schweintzger G et al (2001) Prevention of respiratory syncytial virus (RSV) infection in preterm infants with palivizumab (GERMAN). Monatsschr Kinderheilkd 149:176–178
4. American Academy of Pediatrics, Committee on Infectious Diseases (1998) Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 102:1211–1216
5. Resch B, Urlesberger B, Müller W, Berger A (2004) Recommendations for respiratory syncytial virus prophylaxis with palivizumab (Synagis®) — update 2003 (GERMAN). Monatsschr Kinderheilkd 152:223–224
6. Simoes EA (1999) Respiratory syncytial virus infection. Lancet 354:847–852
7. Sommer C, Resch B, Simões EA (2011) Risk factors for severe respiratory syncytial virus lower respiratory tract infection. Open Microbiol J 5:144–154
8. Resch B, Pasnocht A, Gusenleitner W, Müller W (2005) Rehospitalisations for respiratory disease and respiratory syncytial virus infection in preterm infants of 29-36 weeks gestational age. J Infect 50:397–403
9. Law BJ, Langley JM, Allen U, Paes B, Lee DS, Mitchell I et al (2004) The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 23:806–814
10. Figueras-Aloy J, Carbonell-Estrany X, Quero J; IRIS Study Group (2004) Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33–35 weeks in Spain. Pediatr Infect Dis J 23:815–820
11. Meissner HC (2004) The unresolved issue of risk factors for hospitalization of infants with respiratory syncytial virus infection born after 33–35 weeks gestation. Pediatr Infect Dis J 23:821–823
12. Resch B, Sommer C, Nuijten MJ, Seidinger S, Walter E, Schoellbauer V et al (2012) Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria. Pediatr Infect Dis J 31:e1–e8
13. Simoes EA (2003) Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr 143(5 Suppl):S118–126
14. Simoes EA, King SJ, Lehr MV, Groothuis JR (1993) Preterm twins and triplets. A high-risk group for severe respiratory syncytial virus infection. Am J Dis Child 147:303–306
15. Meissner HC (2016) Viral bronchiolitis in children. N Engl J Med 374:62–72
16. Carbonell-Estrany X, Quero J, Bustos G, Cotero A, Doménech E, Figueras-Aloy J et al (2000) Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study. IRIS Study Group. Pediatr Infect Dis J 19:592–597
17. Groothuis JR, Simoes EAF, Levin MJ, Hall CB, Long CE, Rodriguez WJ et al (1993) Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 329:1524–1530
18. The IMpact-RSV Study Group (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102:531–537
19. Homaira N, Rawlinson W, Snelling TL, Jaffe A (2014) Effectiveness of palivizumab in preventing RSV hospitalization in high-risk children: a real-world perspective. Int J Pediatr 2014:571609
20. Paes B, Mitchell I, Li A, Harimoto T, Lanctot KL (2013) Respiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005-2012) compared to other international registries. Clin Develop Immunol 2013:917068
21. Romero JR (2003) Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage. Pediatr Infect Dis J 22:S46–S54
22. Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J (2003) Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J 22:823–827
23. Simon A, Nowak H, Sterz R (2011) Use of palivizumab in Germany: data from 2002-2007. Klin Padiatr 223:292–298
24. Groothuis JR (2003) Safety of palivizumab in preterm infants 29 to 32 weeks’ gestational age without chronic lung disease to prevent serious respiratory syncytial virus infection. Eur J Clin Microbiol Infect Dis 22:414–417
25. Doering G, Gusenleitner W, Belohradsky BH, Burdach S, Resch B, Liese JG (2006) The risk of respiratory syncytial virus-related hospitalizations in preterm infants of 29 to 35 weeks’ gestational age. Pediatr Infect Dis J 25:1188–1190
26. Mitchell I, Tough S, Gillis L, Majaesic C (2006) Beyond randomized controlled trials: a “real life” experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab. Pediatr Pulmonol 41:1167–1174
27. Purcell K, Driscoll FJ (2004) Children’s Hospital respiratory syncytial virus database: risk factors, treatment and hospital course in 3308 infants and young children, 1991 to 2002. Pediatr Infect Dis J 23:418–423
28. Sampalis JS, Langley J, Carbonell-Estrany X, Paes B, O’Brien K, Allen U et al (2008) Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation. Med Decis Making 28:471–480
29. Paes B, Steele S, Janes M, Pinelli J (2009) Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks’ gestational age in Canada. Curr Med Res Opin 25:1585–1591
30. Carbonell-Estrany X, Simões EA, Fullarton JR, Ferdynus C, Gouyon JB, European RSV Risk Factor Study Group (2010) Validation of a model to predict hospitalization due to RSV of infants born at 33-35 weeks’ gestation. J Perinat Med 38:411–417
31. Simões EA, Carbonell-Estrany X, Fullarton JR, Rossi GA, Barberi I, Lanari M, European RSV Risk Factor Study Group (2011) European risk factors’ model to predict hospitalization of premature infants born 33-35 weeks’ gestational age with respiratory syncytial virus: validation with Italian data. J Matern Fetal Neonatal Med 24:152–157
32. Ryan VM, Langley JM, Dodds L, Andreou P (2016) Estimating respiratory syncytial virus-associated hospitalization in the first year of life among infants born at 32–35 weeks of gestation. Pediatr Infect Dis J 35:851–855
33. Shi T, Balsells E, Wastnedge E, Singleton R, Rasmussen ZA, Zar HJ et al (2015) Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: Systematic review and meta-analysis. J Glob Health 5:020416
34. Mosalli R, Abdul Moez AM, Janish M, Paes B (2015) Value of a risk scoring tool to predict respiratory syncytial virus disease severity and need for hospitalization in term infants. J Med Virol 87:1285–1291
35. American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee (2014) Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 134:415–420